Medtronic Q2 revenue $8.4B (+5.3%); raises FY25 organic growth and EPS guidance

Medtronic plc

2025-Q2 EPS reported $1.79 vs consensus $1.59 ▲ beat (+12.3%)

GAAP diluted EPS $0.99 (up 46% YoY); non-GAAP diluted EPS $1.26 (up 1% as reported, 8% constant currency).
Revenue $8.403B, organic growth 5.0%; driven by TAVR, PFA, leadless pacemakers, Diabetes, Spine, Neuromodulation.
FY25 organic revenue growth guidance raised to 4.75%-5% from 4.5%-5%; non-GAAP EPS guidance raised to $5.44-$5.50 from $5.42-$5.50.
Diabetes revenue $686M (+12.4% as reported, +11% organic) on continued adoption of MiniMed 780G AID system.
Cardiovascular portfolio revenue $3.102B (+6.1% as reported, +5.6% organic) with high-single digit growth in Structural Heart (Evolut FX+ TAVR launch).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.